Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes

Journal of Clinical Microbiology

Volumn 39, Issue 12, 2001, Pages 4344-4348

  Touze A ^a   De Sanjose S ^a   Coursaget, P ^a   Almirall, M R ^a   Palacio, V ^a   Meijer, C J L M ^a   Kornegay, J ^a   Bosch, F X ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTITUTION; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SPAIN; UTERINE CERVIX CYTOLOGY; VIRUS PARTICLE; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROSTITUTION; SEROEPIDEMIOLOGIC STUDIES; TUMOR VIRUS INFECTIONS; VIRION;

EID: 0035205653     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.39.12.4344-4348.2001     Document Type: Article

References (41)

1. Stability over time of serum antibody levels to human papillomavirus type 16
2. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls: A longitudinal cohort study
3. No serological evidence for non-sexual spread of HPV 16
4. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: A case-control study in Spain and Colombia
5. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
6. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women
7. Comparison of human papillomavirus type 16, 18, and 6 capsid antibody responses following incident infection
8. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
9. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
10. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and required cell surface heparan sulfate
11. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepitheliel neoplasia
12. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia: I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome
13. The use of general primers GP5 and GP6 elongated at their 3' ends with conserved sequences improves human papillomavirus detection by polymerase chain reaction
14. Seropositivities to human papillomavirus type 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior
15. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high risk area for cervical cancer
16. Improved amplification of genital human papillomavirus
17. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
18. Persistence of type specific human papillomavirus infection among cytologically normal women
19. Transience of cervical HPV infection in sexually active young women with normal cervicovaginal cytology
20. Natural history of cervicovaginal papillomavirus infection in young women
21. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings
22. A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16
23. High-risk human papillomavirus is sexually transmitted: Evidence from a follow up study of virgins starting sexual activity (intercourse)
24. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study
25. Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells
26. Detection of antibodies against the human papillomavirus (HPV) type 16 virions by ELISA using recombinant HPV 16 L1 capsids produced by recombinant baculovirus
27. Human papillomavirus and cancer: The epidemiological evidence
28. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain
29. Estimates of the worldwide incidence of 25 major cancers in 1990
30. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women
31. PCR detection of human papillomavirus: Comparison between MY09/MY11 and GP5+/GP6+ primers systems
32. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
33. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix
34. Human papillomaviruses and cervical neoplasia: A model for carcinogenesis
35. HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates
36. The L1 major capsid protein of human papillomavirus type 16 variants affects the yield of virus-like particle produced in an insect cells expression system
37. Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection
38. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women
39. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16
40. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1